The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections

Invasive pulmonary aspergillosis (IPA), invasive mucormycosis (IM), and invasive fusariosis (IF) are associated with high mortality and morbidity. Fosmanogepix (FMGX) is a first-in-class antifungal in clinical development with demonstrated broad-spectrum activity in animal models of infections. We s...

Descripción completa

Detalles Bibliográficos
Autores principales: Gebremariam, Teclegiorgis, Gu, Yiyou, Alkhazraji, Sondus, Youssef, Eman, Shaw, Karen Joy, Ibrahim, Ashraf S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295579/
https://www.ncbi.nlm.nih.gov/pubmed/35670592
http://dx.doi.org/10.1128/aac.00380-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295579/
https://www.ncbi.nlm.nih.gov/pubmed/35670592
http://dx.doi.org/10.1128/aac.00380-22

Ejemplares similares